Recombinant Human Hepassocin/FGL1 Avi Fc Chimera Protein, CF

Measured by its binding ability in a functional ELISA. When Recombinant Human LAG-3 Fc Chimera Protein (2319-L3) is immobilized at 2.50 µg/mL (100 µL/ well), Biotinylated Recombinant Human Hepassocin/FGL1 Avi-tag Fc Chimera (Catalog # AVI10573) binds with an ED50 of 0.250-2.50 μg/mL.

2 μg/lane of Biotinylated Recombinant Human Hepassocin/FGL1 Avi-tag Fc Chimera Protein (Catalog # AVI10573) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 59-68 kDa and 120-140 kDa, respectively.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human Hepassocin/FGL1 Avi Fc Chimera Protein, CF Summary

• Additional Information: Biotinylated
• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Human LAG-3 Fc Chimera Protein (Catalog # 2319-L3) is immobilized at 2.50 µg/mL (100 µL/ well), Biotinylated Recombinant Human Hepassocin/FGL1 Avi-tag Fc Chimera (Catalog # AVI10573) binds with an ED 50 of 0.250-2.50 μg/mL.
• Source: Chinese Hamster Ovary cell line, CHO-derived human Hepassocin/FGL1 protein

  Avi-tag

  MD

  Human IgG 1 Fc (Pro100-Lys330)

  IEGR

  Human FGL1 (Leu23-Ile312) Accession # Q08830.3

  N-terminus

  C-terminus

• Accession #: Q08830.3
• N-terminal Sequence: Gly of Avi-tag
• Structure / Form: Disulfide-linked homodimer
  Biotinylated via Avi-tag
• Protein/Peptide Type: Recombinant Proteins
• Purity: >90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 63 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 59-68 kDa, under reducing conditions.

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  12 months from date of receipt, -20 to -70 degreesC as supplied. 1 month, 2 to 8 degreesC under sterile conditions after reconstitution. 3 months, -20 to -70 degreesC under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
• Purity: >90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 500 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human Hepassocin/FGL1 Avi Fc Chimera Protein, CF

• FGL1
• fibrinogen-like 1
• fibrinogen-like protein 1
• Fibrinogen-like-protein 1
• FREP1
• Hepassocin
• hepatocellular carcinoma-related sequence
• Hepatocyte-derived fibrinogen-related protein 1
• HFREP-1
• HFREP1MGC12455
• HP-041
• LFIRE1
• LFIRE-1
• Liver fibrinogen-related protein 1

Background

Hepassocin, also known as Hepatocyte-derived fibrinogen-related protein 1 (HFREP-1) and Fibrinogen-Like Protein 1 (FGL1) (1), is a liver-specific secreted protein belonging to the fibrinogen superfamily whose members share a fibrinogen domain at their C-termini (2). Human Hepassocin/FGL1 is a secreted homodimer consisting of 312 amino acids (aa) with a 22 aa signal sequence and a 290 aa mature protein (3). Mouse and rat Hepassocin/FGL1 share approximately 84% and 83% amino acid identity with human Hepassocin/FGL1, respectively. Human Hepassocin/FGL1 binds LAG-3 through its fibrinogen-like domain independently of MHC class II (4). Hepassocin/FGL1 inhibits antigen-specific T cell activation, with its elevated presence in plasma of cancer patients indicating poor prognoses (4). Other than this role in cancer progression, Hepassocin/FGL1 also has restorative function for liver cells. It is upregulated during liver regeneration following partial hepatectomy (5), and stimulates proliferation of hepatocytes in vivo and improves prognoses with fulminant hepatic failure in rats (6). Its expression is regulated in Hep G2 cells by interleukin-6 (IL-6) and is found in the serum in both bound and unbound states as an acute phase reactant (7). Our Avi-tag Biotinylated human Hepassocin/FGL1 Fc Chimera features biotinylation at a single site contained within the Avi-tag, a unique 15 amino acid peptide. Protein orientation will be uniform when bound to streptavidin-coated surface due to the precise control of biotinylation and the rest of the protein is unchanged so there is no interference in the protein's bioactivity.

1. Yamamoto, T. et al. (1993) Biochem. Biophys. Res. Commun. 2:681.
2. Zhang, S.M. et al. (2008) Innate Immun. 14:175.
3. Hara, H. et al. (2001) Biochim. Biophys. Acta. 1520:45.
4. Wang, J. et al. (2019) Cell. 176:334.
5. Yu, HT. et al. (2009) J. Biol. Chem. 284:13335.
6. Li, C.Y. et al. (2010) Gut. 59:817.
7. Liu, Z. and C. Ukomadu. (2008) Biochem. Briophys. Res. Commun. 365:729.

Bioinformatics

• Uniprot:
  • Q08830.3()